Icon, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has signed a three-year agreement with Pfizer. Under the terms of the agreement, Pfizer has the right to extend the term for up to an additional two years. Financial details of the agreement were not disclosed.

The new agreement builds on the companies’ existing relationship, under which Icon provides global expertise in the planning, execution, management and conduct of clinical trials.

Ciaran Murray, Icon’s CEO, said, "The progression of our relationship with Pfizer is a recognition of Icon’s capabilities in supporting drug development efforts. We look forward to continuing our relationship with Pfizer to help advance its development pipeline and innovation in the drug development process.”

Parexel International, a global biopharmaceutical services provider, also has signed a services agreement with Pfizer. Under the terms of this agreement, Parexel will continue to provide global clinical research and development services to Pfizer in support of clinical development programs across its portfolio. Terms of the agreement were not disclosed.

“Parexel will continue to leverage its proven clinical processes and expertise to help Pfizer conduct clinical trials and accomplish its drug development goals,” said Josef von Rickenbach, chairman and chief executive officer, Parexel International. “Our team is focused on applying dynamic and innovative operational models to help Pfizer develop drugs to improve health and treat diseases for patients around the world.”